Allogene Q1 net loss $42.6 million, or $0.18 a share; cash $266.9 million

• Allogene Therapeutics posted a Q1 net loss of $42.6 million, or $0.18 per share, including $8.3 million in non-cash stock-based compensation.
• R&D expense totaled $32 million, while G&A expense was $14.1 million.
• Cash, cash equivalents, and investments were $266.9 million as of March 31; April public offering raised gross proceeds of $200.4 million, extending cash runway into Q1 2029.
• 2026 operating cash expense guidance increased to about $165 million, while GAAP operating expenses outlook rose to about $225 million including estimated non-cash stock-based compensation of about $35 million.
• In planned interim futility analysis of Phase 2 ALPHA3, 58.3% of patients in cema-cel arm achieved MRD clearance versus 16.7% in observation arm, a 41.6 percentage-point gap; interim EFS analysis expected mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131602PRIMZONEFULLFEED9719098) on May 13, 2026, and is solely responsible for the information contained therein.